
    
      Primary purpose: To demonstrate the bioequivalence of Saxagliptin and Metformin from a 5 mg
      Saxagliptin/500 mg Metformin XR FDC tablet relative to 5 mg Onglyza™ and 500 mg Glifage® XR
      (marketed in Brazil by Merck S.A.) tablets administered together in both the fasted and fed
      states.
    
  